Background: Semuloparin is a novel ultra-low-molecular-weight heparin under development for venous thromboembolism (VTE) prevention in patients at increased risk, such as surgical and cancer patients. Objectives: Three Phase III studies compared semuloparin and enoxaparin after major orthopedic surgery: elective knee replacement (SAVE-KNEE), elective hip replacement (SAVE-HIP1) and hip fracture surgery (SAVE-HIP2). Patients/Methods: All studies were multinational, randomized and double-blind. Semuloparin and enoxaparin were administered for 7-10days after surgery. Mandatory bilateral venography was to be performed between days 7 and 11. The primary efficacy endpoint was a composite of any deep vein thrombosis, non-fatal pulmonary embolism or all-cause death. Safety outcomes included major bleeding, clinically relevant non-major (CRNM) bleeding, and any clinically relevant bleeding (major bleeding plus CRNM). Results: In total, 1150, 2326 and 1003 patients were randomized in SAVE-KNEE, SAVE-HIP1 and SAVE-HIP2, respectively. In all studies, the incidences of the primary efficacy endpoint were numerically lower in the semuloparin group vs. the enoxaparin group, but the difference was statistically significant only in SAVE-HIP1. In SAVE-HIP1, clinically relevant bleeding and major bleeding were significantly lower in the semuloparin vs. the enoxaparin group. In SAVE-KNEE and SAVE-HIP2, clinically relevant bleeding tended to be higher in the semuloparin group, but rates of major bleeding were similar in the two groups. Other safety parameters were generally similar between treatment groups. Conclusions: Semuloparin was superior to enoxaparin for VTE prevention after hip replacement surgery, but failed to demonstrate superiority after knee replacement surgery and hip fracture surgery. Semuloparin and enoxaparin exhibited generally similar safety profiles. © 2012 International Society on Thrombosis and Haemostasis.

Semuloparin for prevention of venous thromboembolism after major orthopedic surgery: Results from three randomized clinical trials, SAVE-HIP1, SAVE-HIP2 and SAVE-KNEE

GROSSI, PAOLO ANTONIO;
2012-01-01

Abstract

Background: Semuloparin is a novel ultra-low-molecular-weight heparin under development for venous thromboembolism (VTE) prevention in patients at increased risk, such as surgical and cancer patients. Objectives: Three Phase III studies compared semuloparin and enoxaparin after major orthopedic surgery: elective knee replacement (SAVE-KNEE), elective hip replacement (SAVE-HIP1) and hip fracture surgery (SAVE-HIP2). Patients/Methods: All studies were multinational, randomized and double-blind. Semuloparin and enoxaparin were administered for 7-10days after surgery. Mandatory bilateral venography was to be performed between days 7 and 11. The primary efficacy endpoint was a composite of any deep vein thrombosis, non-fatal pulmonary embolism or all-cause death. Safety outcomes included major bleeding, clinically relevant non-major (CRNM) bleeding, and any clinically relevant bleeding (major bleeding plus CRNM). Results: In total, 1150, 2326 and 1003 patients were randomized in SAVE-KNEE, SAVE-HIP1 and SAVE-HIP2, respectively. In all studies, the incidences of the primary efficacy endpoint were numerically lower in the semuloparin group vs. the enoxaparin group, but the difference was statistically significant only in SAVE-HIP1. In SAVE-HIP1, clinically relevant bleeding and major bleeding were significantly lower in the semuloparin vs. the enoxaparin group. In SAVE-KNEE and SAVE-HIP2, clinically relevant bleeding tended to be higher in the semuloparin group, but rates of major bleeding were similar in the two groups. Other safety parameters were generally similar between treatment groups. Conclusions: Semuloparin was superior to enoxaparin for VTE prevention after hip replacement surgery, but failed to demonstrate superiority after knee replacement surgery and hip fracture surgery. Semuloparin and enoxaparin exhibited generally similar safety profiles. © 2012 International Society on Thrombosis and Haemostasis.
2012
Anticoagulant; Enoxaparin; Orthopedic surgery; Prophylaxis; Semuloparin; Venous thromboembolism; Hematology
Lassen, M. R; Fisher, W.; Mouret, P.; Agnelli, G.; George, D.; Kakkar, A.; Mismetti, P.; Turpie, A. G. G.; Leizorovicz, A.; Borris, L. C.; Buyse, M.; Sturbois, G.; Fisher, M. R.; White, R. H.; A., Alvarisqueta; Horsley, M.; Jackson, D.; Salem, H.; Chong, B.; Richards, B.; Baltrukevich, S.; Pisesky, W.; Kim, P.; Martinez, S.; Aguilera, B.; Rocha, C.; Reyes, A.; Botero Lopez, R.; Trc, T.; Pink, T.; Ludvik, J.; Krbec, M.; Repko, M.; Mikkelsen, S.; Gebuhr, P.; Lassen, M.; Borgwardt, A.; Märtson, A.; Kelk, M.; Kööp, A.; Tyllianakis, M.; Kapetanos, G.; Christodoulou, A.; Kocius, M.; Smailys, A.; Sierra Perez, M.; Gomez Sanchez, E.; Vazquez Montana, M.; Resendiz Orozco, S.; Ramos Morales, T.; Berumen Nafarrate, E.; Synder, M.; Skowronski, J.; Kruczynski, J.; Blacha, J.; Kwiatkowski, K.; Tkaczyk, S.; Cirstoiu, C.; Popescu, G.; Purghel, F.; Botez, P.; Vermesan, H.; Poenaru, D.; Yakusevich, V.; Akhtyamov, I.; Zagorodniy, N.; Kornilov, N.; Linnik, S.; Ivanov, P.; Dryagin, V.; Safronov, A.; Magomedov, K.; Murylev, V.; Parfeev, S.; Ezhov, I.; Kuropatkin, G.; Abolin, A.; Van zyl, L.; Oelofse, L.; Swart, H. J.; Stathoulis, B.; Sulyma, V.; Kostrub, O.; Shyshka, I.; Chernyak, V.; Olinichenko, G.; Korzh, M.; Browne, R.; Murray, R. M.; Ward, J.; Williams, D.; Strain, R.; Gimbel, J.; Tapadiya, D.; Hollmann, M.; Jove, M.; Berkowitz, R.; Kilgore, J.; Dabezies, E.; D'Angelo, G.; Minkowitz, H.; King, R.; Han, D.; Gill, G.; Lorch, D.; Siff, S.; Shah, M.; Jazayeri, M. J.; Cottrell, W.; Steinman, H.; Papilion, J.; Poole, C.; Schwappach, J.; Tetsworth, K.; Carroll, P.; Kezlia, A.; Fisher, W.; Kim, P.; Guerrero, C.; Soza, F.; Paredes, O.; Amenabar, P.; Martinez, S.; Sanchez, A.; Aguilera, B.; Reyes, A.; Perez, R.; Botero, R.; Trc, T.; Pink, T.; Filip, L.; Krbec, M.; Repko, M.; Kana, J.; Mikkelsen, S.; Jensen, N.; Søballe, K.; Gebuhr, P.; Lassen, M.; Borgwardt, A.; Märtson, A.; Kelk, M.; Kööp, A.; Leppilahti, J.; Väänänen, H.; Jokipii, P.; Pesola, M.; Kröger, H.; Kurth, A.; Lützner, J.; Craiovan, B.; Graichen, H.; Perka, C.; Tyllianakis, M.; Verettas, D.; Babis, G.; Kapetanos, G.; Christodoulou, A.; Dadi, A.; Rajagopalan, I.; Shah, H.; Raju, P.; Shah, V.; Tapasvi, S.; Pagare, S.; Boddapalli, U.; Borghi, B.; Grossi, PAOLO ANTONIO; Parise, P.; Silingardi, M.; Buffone, A.; Davià, G.; Fattorini, F.; Gomez Sanchez, E.; Resendiz Orozco, S.; Zuqui, M. A.; Berumen Nafarrete, E.; Sepulveda Oyervides, V.; Melby, B.; Sletten, S.; Dietze, A.; Lian, O.; Risberg, E.; Alfredo Arones, V.; Cotrina, R.; Marticorena, O.; Molano, A. M.; San Pedro, P. C.; Synder, M.; Skowronski, J.; Kruczynski, J.; Blacha, J.; Tkaczyk, S.; Kwiatkowski, K.; Cirstoiu, C.; Popescu, G.; Purghel, F.; Botez, P.; Vermesan, H.; Poenaru, D.; Tarnau, A.; Yakusevich, V.; Akhtyamov, I.; Zagorodniy, N.; Kornilov, N.; Linnik, S.; Ivanov, P.; Dryagin, V.; Safronov, A.; Magomedov, K.; Murylev, V.; Parfeev, S.; Ezhov, I.; Kuropatkin, G.; Abolin, A.; Steno, B.; Knapec, L.; Ozorak, M.; Van zyl, L.; Oelofse, L.; Swart, H. J.; Mclennan Smith, R. A.; Peidro, L.; Castellet, E.; Gomar, F.; Fernandez De Retana, P.; Ryttberg, L.; Horn Af, A.; Minne, B.; Nilsson, K.; Johansson, J.; Chen, Y. J.; Thanainit, C.; Tanavalee, A.; Altintas, F.; Aydogdu, S.; Alpaslan, M.; Tozun, R.; Erdemli, B.; Skobenko, O.; Gerasimenko, S.; Polyvoda, O.; Chernyak, V.; Olinichenko, G.; Chornyy, V.; Browne, R.; Murray, R.; Ward, J.; Williams, D.; Strain, R.; Gimbel, J.; Tapadiya, D.; Hollmann, M.; Jove, M.; Berkowitz, R.; Kilgore, J.; Dabezies, E.; Boshnakov, D.; Iotov, A.; Penchev, P.; Belzile, E.; Kim, P.; Bredo, L.; Azar, C.; Soza, F.; Paredes, O.; Botello, E.; Tang, P.; Jiang, B.; Zhou, F.; Xu, Y.; Chen, T.; Liu, F.; Liao, W.; Leal, E.; Aguilera, B.; Salas, G.; Krivohlavek, M.; Mahovsky, D.; Divis, P.; Sir, M.; Pink, T.; Duus, B.; Gebuhr, P.; Overgaard, S.; Madsen, B.; Leppilahti, J.; Null, Pesola M.; Jokipii, P.; Malizos, K.; Verettas, D.; Kapetanos, G.; Christodoulou, A.; Kyriakidis, A.; Naresh, S.; Peddyreddy, G. R.; Null, Bharat M.; Sushrut, B.; Kumar, A.; Mutha, S.; Pagare, S.; Boddapalli, U.; Dadi, A.; Borghi, B.; D'Ambrosio, A.; Miletto, A.; Guido, G.; Brunetto, B.; Saenz Cabrera, V. M.; Berumen Nafarrete, E.; Hernandez Ramirez, J.; Null, Otsuka de HoyosR; Gomez Sanchez, E.; Leal Rojas, E.; Resendiz Orozco, S.; Cotrina, R.; Tochio, C.; Skowronski, J.; Kruczynski, J.; Blacha, J.; Tkaczyk, S.; Monteiro, J.; Felicissimo, P.; Nascimento, A.; Cirstoiu, C.; Popescu, G.; Purghel, F.; Botez, P.; Vermesan, H.; Poenaru, D.; Tarnau, A.; Yakusevich, V.; Akhtyamov, I.; Kornilov, N.; Ivanov, P.; Dryagin, V.; Safronov, A.; Sergeev, S.; Rodoman, G.; Belenkiy, I.; Savintsev, A.; Kuropatkin, G.; Abolin, A.; Murylev, V.; Van zyl, L.; Jansen van rensburg, J. H.; Oelofse, L.; Stathoulis, B.; Lukhele, M.; Peidro, L.; Salvador, A.; Ryttberg, L.; Pettersson, L.; Horn, A. F. A.; Minne, B.; Altintas, F.; Durak, K.; Avkan, C.; Gurbuz, H.; Ozturk, I.; Ozkan, Y.; Ustaoglu, G.; Gerasimenko, S.; Gatsak, V.; Skobenko, O.; Chernyak, V.; Ward, J.; Williams, D.; Tapadiya, D.; Krumins, K.; Dabezies, E.; Minkowitz, H.; Schwappach, J.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2061538
 Attenzione

L'Ateneo sottopone a validazione solo i file PDF allegati

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 22
social impact